FGF receptor inhibitors: role in cancer therapy. - Test2 - elhamkhani - TriplyDB

FGF receptor inhibitors: role in cancer therapy.

FGF receptor inhibitors: role in cancer therapy.

http://www.wikidata.org/entity/Q37981986

about

Fibroblast growth factor receptor signaling as therapeutic targets in gastric cancer Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review.Toward precision medicine of breast cancer FGF receptors: cancer biology and therapeutics Growth factor and Th2 cytokine signaling pathways converge at STAT6 to promote arginase expression in progressive experimental visceral leishmaniasis Angiogenesis and antiangiogenic agents in cervical cancer.Genome-Wide Loss of Heterozygosity and DNA Copy Number Aberration in HPV-Negative Oral Squamous Cell Carcinoma and Their Associations with Disease-Specific Survival.Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy.Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma.Fibroblast growth factors, old kids on the new block.Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial Emerging VEGF-receptor inhibitors for colorectal cancer.Targeting fibroblast growth factor pathways in prostate cancer.Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.New biological treatments for gynecological tumors: focus on angiogenesis.Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.Recombinant expression in E. coli of human FGFR2 with its transmembrane and extracellular domains.Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP)Anti-Angiogenic Drugs: Involvement in Cutaneous Side Effects and Wound-Healing Complication.Optimization of Bioactive Polyphenols Extraction from Picea Mariana Bark.Studies of genes involved in craniofacial development and tumorigenesis: FGF3 contributes to isolated oral clefts and may interact with PAX9.Fluorinated Analog NMR s of Organosulfur Compounds from Garlic (Allium sativum): Synthesis, Chemistry and Anti-Angiogenesis and Antithrombotic Studies.Antiangiogenic effects of cucurbitacin-I.[SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling].FGFR4 as a Biomarker in Squamous Cell Cancers of Mouth and Oropharynx

P2860

Q26764932-D650537A-A50A-4B1A-BFD2-934C782D17C1 Q26998955-FF9556E5-AF96-4057-99E1-828BF137DA4E Q27853178-C029A0E7-1462-426D-88B1-F86E61BC5D49 Q28073967-B2F3E31C-CFFE-47A8-A084-FC6013759AE3 Q28291186-FF577BBF-4395-4F0B-AB2B-C8FB013DAC94 Q28540097-7AA813F0-B067-4D59-909E-902875C364E8 Q34655335-449BB3F7-CD74-45B1-9EF1-A123C6F5A24E Q35738663-82E262E0-90E3-4EF9-A4B2-522EE0C160EF Q35881055-CCCA5B9B-9439-49AE-97C6-791D4C335C91 Q36528389-23761B71-3E69-4D11-B647-003A33B74FB8 Q36923642-32200F7F-FF81-480E-896E-AAE48F4714D9 Q37526488-4A6BFE57-050A-4F5E-B3FA-4FBFC8DA06DC Q38065241-C955EF84-4EBA-4A47-B060-CF3DD2687218 Q38139831-568F8CB8-A76B-4B95-930C-8CD4DDA02DFD Q38175454-112C894F-05C2-4AA8-AED4-4ACF5790F314 Q38175506-A43A3636-52F7-496B-BEE4-C2B7673CC34F Q38212165-593BCFF7-6705-46DE-9263-3A07BA01DFAF Q38259982-4FFAD8B3-BC1D-4CF9-9C1C-C64E4059AEA4 Q38979882-4B78E465-AE54-4EE9-84B9-9D331355BB6F Q39257661-AE5DCCCC-5A0E-4BF5-AB03-64C9802EF86D Q40983650-8AD7DA91-8B9A-422A-804D-D5C5B9B24B20 Q42240146-5C80B95C-95CF-4F38-B83C-F3195C4767AB Q42926957-DDC5DCF9-04A2-4E44-B0B3-5605DFBB9A82 Q47774023-96370EF7-29D9-4FBF-A3C7-26642407C958 Q48875118-BE2B478C-DEAC-4C45-9F3D-53C7218D9CD1 Q49575128-03AFA876-8ED7-4B65-82E6-65944574CE28 Q53057689-089BC9E8-5906-4C1B-985F-6ADEE9154CA7 Q54401454-4FBE558C-FFC5-4409-876A-8CFC2D717953 Q57556242-33077305-0B6A-47D9-A3A4-29F730BCE4B3

P2860

FGF receptor inhibitors: role in cancer therapy.

http://www.wikidata.org/entity/Q37981986

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

FGF receptor inhibitors: role in cancer therapy.

@en

FGF receptor inhibitors: role in cancer therapy.

@nl

type

label

FGF receptor inhibitors: role in cancer therapy.

@en

FGF receptor inhibitors: role in cancer therapy.

@nl

prefLabel

FGF receptor inhibitors: role in cancer therapy.

@en

FGF receptor inhibitors: role in cancer therapy.

@nl

P1433

Q37981986-A11AAA24-2453-479F-A71F-85EC1AC945CF

P1476

Q37981986-5AFCDF3C-7C75-40CB-8ECD-D5C6F57FF850

P2093

Q37981986-1177D480-9F59-4C7A-AA15-877845C069B6

Q37981986-4B08F225-7837-4829-B45A-481D4E978AE2

Q37981986-887E2491-5D93-4FDB-B98C-2CC550F0A175

P2860

Q37981986-00D1A4C4-3620-468A-BF08-938E9BF0B8B2

Q37981986-0490989E-2963-40EF-B7F5-F12225A38FDA

Q37981986-0BDE9E08-8E60-4175-A10A-37A6BC583962

Q37981986-0CA224A5-81B8-46E7-8357-E9F87A8B3902

Q37981986-15903335-0866-4A43-830D-75CBB0A997E0

Q37981986-1C1F678D-772A-40FE-9D4D-34F931E8F5A3

Q37981986-23EFB677-3717-495C-B046-88B8FB071883

Q37981986-26839AB4-CDDA-4639-876A-E6A15100C17A

Q37981986-26AC871B-8A98-4717-A5B5-73AAA1B9C4E5

Q37981986-26FD8BFB-8F72-4796-92FE-4953E9A211FE

P2888

Q37981986-A3612700-61D2-4A9F-84CE-D4C0FF7594F9

P304

Q37981986-E285C179-34B1-4FBF-9BA2-E1A92233FA4D

P31

Q37981986-77FDEA9A-5F2E-4471-96B2-28858DC4A8D3

P356

Q37981986-C31D501B-4D02-4B5C-8B8C-E4D96BE7283A

P433

Q37981986-091B1E71-001D-4E9B-84E2-21F9891F75B6

P478

Q37981986-396C5FE3-FBE1-4577-A4A2-E3F7E9526278

P50

Q37981986-22C9C183-04AA-4A20-B263-C220698CB6EE

P577

Q37981986-0BAC2B6A-3A3D-48BF-B9DB-2E599C4007FE

P698

Q37981986-D6DE65D4-A844-4E17-88C6-43D1D24DE360

P356

S11912-012-0225-0

P1433

Current Oncology Reports

P1476

FGF receptor inhibitors: role in cancer therapy.

@en

P2093

Jesus Corral

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

L Rhoda Molife

http://www.w3.org/2001/XMLSchema#string

P2860

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

Cellular signaling by fibroblast growth factor receptors

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation.

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.

P2888

s11912-012-0225-0

P304

111-119

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-012-0225-0

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

Gennaro Daniele

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22311684

http://www.w3.org/2001/XMLSchema#string